CAS NO: | 99011-78-6 |
包装: | 100mg |
市场价: | 500元 |
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 276.76 |
Cas No. | 99011-78-6 |
Formula | C14H17ClN4 |
Solubility | ≥3.59 mg/mL in EtOH with ultrasonic; ≥5.54 mg/mL in DMSO with gentle warming and ultrasonic; ≥7.34 mg/mL in H2O with ultrasonic |
Chemical Name | 1-isobutyl-1H-imidazo[4,5-c]quinolin-4(5H)-imine hydrochloride |
Canonical SMILES | CC(CN1C=NC2=C1C3=CC=CC=C3NC2=N)C.Cl |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Cell experiment:[1] | |
Cell lines | Thioglycollate-elicited peritoneal cells from wild-type (C57BL/6) and MyD88-deficient mice |
Reaction Conditions | 101~ 104nM imiquimod for 24 h incubation |
Applications | Imiquimod increased TNF-α and IL-12p40 production in IFN-γ-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner. |
Animal experiment:[2] | |
Animal models | Female Hartley guinea pigs, 400 ~ 500 g |
Dosage form | 5 mg/kg Administered intravaginally every 12 h for five days beginning 12 h after genital HSV-2 inoculation |
Applications | Imiquimod (5 mg/kg, intravaginally, twice daily) reduced vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection. Imiquimod exhibited potent anti-HSV activityin vivodue to cytokine induction and enhancement of cell-mediated responses. |
Note | The technical data provided above is for reference only. |
References: 1. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunology, 2002, 3(2): 196-200. 2. Harrison CJ, Jenski L, Voychehovski T, et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Research, 1988, 10(4-5): 209-223. |